San Diego Venture Group: State of Venture Investing in Life Sciences

Venture capital investing has been contracting this year for both drug development and medical device startups, but what does that mean for companies searching for capital? Add a sluggish economic recovery, a bitter Presidential election, and continuing debates over healthcare policies, and you have one uncertain future. The San Diego Venture Group has asked four luminaries of venture capital—Kevin Kinsella, Nim Shah, Mike Grey, and Heath Lukatch—to call it as they see it. Xconomy San Diego Editor Bruce V. Bigelow has agreed to moderate. More information and online registration is here.